Corp. VP & Chief HR Officer Hicks Cameron P was granted 1,422 shares, increasing direct ownership by 14% to 11,408 units (SEC Form 4)

$TFX
Medical/Dental Instruments
Health Care
Get the next $TFX alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hicks Cameron P

(Last) (First) (Middle)
C/O 550 E. SWEDESFORD ROAD
SUITE 400

(Street)
WAYNE PA 19087

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
TELEFLEX INC [ TFX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Corp. VP & Chief HR Officer
3. Date of Earliest Transaction (Month/Day/Year)
03/04/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/04/2025 A(1) 1,422 A $0 11,407.6473 D
Common Stock 36.023 I By 401(k) Trustee
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option / (Right to Buy) $130.79 03/04/2025 A 10,040 (2) 03/04/2035 Common Stock 10,040 $0 10,040 D
Explanation of Responses:
1. Restricted Stock Unit Award granted pursuant to the Teleflex Incorporated 2023 Stock Incentive Plan. 25% of the shares underlying the award will vest on each of 3/4/2026, 3/4/2027, 3/4/2028 and 3/4/2029, subject to Reporting Person's continuous service to the Issuer through each such vesting date.
2. One third of the shares underlying the stock option will vest on each of 3/4/2026, 3/4/2027 and 3/4/2028, subject to Reporting Person's continuous service to the Issuer through each such vesting date.
Remarks:
Daniel V. Logue with POA for Cameron P. Hicks 03/06/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $TFX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TFX

DatePrice TargetRatingAnalyst
3/4/2025$235.00 → $140.00Neutral → Underperform
BofA Securities
2/28/2025$220.00 → $155.00Outperform → Sector Perform
RBC Capital Mkts
2/28/2025Outperform → Mkt Perform
Raymond James
2/28/2025$255.00 → $140.00Overweight → Neutral
Piper Sandler
2/27/2025Mkt Outperform → Mkt Perform
Citizens JMP
7/1/2024$205.00 → $245.00Neutral → Overweight
Piper Sandler
12/4/2023$261.00Equal-Weight → Overweight
Morgan Stanley
6/21/2023Buy → Hold
Needham
More analyst ratings

$TFX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Teleflex Announces Clinical and Real-World Evidence Studies and Physician Educational Opportunities to Be Highlighted at the 2025 American Urological Association (AUA) Annual Meeting

    WAYNE, Pa., April 24, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the presentation of several clinical studies at the 2025 American Urological Association Annual Meeting, which is being held in Las Vegas from April 26 - 29, 2025. These studies contribute to the expanding body of clinical and real-world evidence supporting innovations in benign prostatic hyperplasia (BPH) treatment and rectal spacing to protect tissue during radiation treatment for prostate cancer. "Understanding how leading treatment options perform—both in rigorous clinical trials and in everyday practice—is essential to empowering the futu

    $TFX
    Medical/Dental Instruments
    Health Care
  • Teleflex Announces First Quarter 2025 Earnings Conference Call Information

    WAYNE, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its first quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, May 1, 2025. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company's website, teleflex.com. An audio replay of the call will be available beginning at 11:00 am Eastern Time on May 1, 2025, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (all ot

    $TFX
    Medical/Dental Instruments
    Health Care
  • Teleflex Receives FDA 510(k) Clearance of the AC3 Range™ Intra-Aortic Balloon Pump (IABP)

    WAYNE, Pa., April 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced FDA 510(k) clearance of the AC3 Range™ Intra-Aortic Balloon Pump (IABP). Leveraging the patented technology of the AC3 Optimus™ IABP, the AC3 Range™ IABP is designed to provide reliable, ongoing IABP support across various patient transport modes, including ambulances and both fixed- and rotary-wing aircrafts. The AC3 Range™ IABP combines the simple interface and proprietary algorithms of the AC3 Optimus™ IABP to deliver the same precisely timed support1 with features designed specifically for challenges unique to transport, including a full-s

    $TFX
    Medical/Dental Instruments
    Health Care

$TFX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$TFX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$TFX
SEC Filings

See more

$TFX
Leadership Updates

Live Leadership Updates

See more
  • DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P

    $ALK
    $AMBC
    $ATI
    $BBWI
    Air Freight/Delivery Services
    Consumer Discretionary
    Property-Casualty Insurers
    Finance
  • Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

    Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE:TFX) and Abbott (NYSE:ABT). With

    $ABT
    $TFX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
  • Teleflex Announces Planned Retirement of Thomas Powell As Chief Financial Officer

    WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that Thomas E. Powell, Teleflex's Chief Financial Officer, has decided to retire as Executive Vice President and Chief Financial Officer, effective April 1, 2025. John R. Deren, who currently serves as Corporate Vice President and Chief Accounting Officer of Teleflex, will succeed Mr. Powell as Executive Vice President and Chief Financial Officer, effective April 2, 2025. Following his retirement, Mr. Powell will serve as a consultant to the company through March 31, 2026 to support continuity and a smooth transition. "Tom has announced his des

    $TFX
    Medical/Dental Instruments
    Health Care

$TFX
Financials

Live finance-specific insights

See more
  • Teleflex Announces First Quarter 2025 Earnings Conference Call Information

    WAYNE, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its first quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, May 1, 2025. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company's website, teleflex.com. An audio replay of the call will be available beginning at 11:00 am Eastern Time on May 1, 2025, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (all ot

    $TFX
    Medical/Dental Instruments
    Health Care
  • Teleflex Announces Quarterly Dividend

    WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable March 17, 2025, to shareholders of record at the close of business on March 7, 2025. Additional information about Teleflex can be obtained from the company's website at teleflex.com. About Teleflex IncorporatedAs a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in

    $TFX
    Medical/Dental Instruments
    Health Care
  • Teleflex Reports Fourth Quarter and Full Year 2024 Financial Results

    WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) (the "Company") today announced financial results for the fourth quarter ended December 31, 2024. Fourth quarter financial summary Revenues of $795.4 million, up 2.8% compared to the prior year period, up 3.2% on an adjusted constant currency basisGAAP diluted EPS from continuing operations of $(2.95), compared to $0.66 in the prior year periodAdjusted diluted EPS from continuing operations of $3.89, compared to $3.38 in the prior year period Full year 2024 financial summary GAAP revenue of $3,047.3 million, up 2.4% compared to the prior year periodAdjusted revenue of $3,061.1 million, excluding the impact f

    $TFX
    Medical/Dental Instruments
    Health Care

$TFX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more